Cholestyramine NDC 68382-528

NDC codes

FDA NDC Directory

Product NDC (as listed)68382-528Labeler and product segments. Claims need a package NDC.

Product NDC at billing width68382-0528Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
68382-528-42	68382052842	378 g in 1 CAN (68382-528-42)Marketed from Aug 1, 2018
68382-528-60	68382052860	60 POUCH in 1 CARTON (68382-528-60) / 9 g in 1 POUCHMarketed from Aug 1, 2018

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Cholestyramine
Generic name (nonproprietary): cholestyramine
Active ingredients: Cholestyramine — 4 g/9g
Dosage form: Powder, For suspension
Route: Oral
Labeler: Zydus Pharmaceuticals (USA) Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 202901
Marketing start: Aug 1, 2018
Listing expires: Dec 31, 2027
Other FDA classes: Bile-acid Binding Activity (Mechanism)
Identifiers: Product ID 68382-528_05ac7932-41c3-4434-8655-d47bfa6db8b0SPL ID 05ac7932-41c3-4434-8655-d47bfa6db8b0SPL set ID acc48703-c15b-4275-aa75-749f1c07dcbbRxCUI 848943UNII 4B33BGI082
Pharmacologic class: Bile Acid Sequestrant

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N468382052842 followed by a unit qualifier and the quantity

Package 68382-0528-42. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 28, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE 1) Cholestyramine for oral suspension is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine for oral suspension may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholes…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 202901

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 202901
Product	Strength	Form · route	Labeler	Product NDC
Cholestyramine	Cholestyramine 4 g/9g	Powder, For suspensionOral	Zydus Lifesciences Limited	70771-1105